caa a22 4500 445882328 CHVBK 20180317145547.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s10157-010-0377-x doi (NATIONALLICENCE)springer-10.1007/s10157-010-0377-x Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy [Elektronische Daten] [Aditi Sinha, Cynthia Nast, Ionut Hristea, Ashley Vo, Stanley Jordan] C1q nephropathy is a rare idiopathic glomerulopathy characterized by mesangial deposition of immunoglobulin and complement with C1q dominance or co-dominance, and the absence of clinical and laboratory evidence of systemic lupus erythematosus. Its clinical course is unpredictable and the response to corticosteroid or cytotoxic treatment is variable. Here, we report two cases of C1q nephropathy, one in a child and one in an adult, both presenting with impaired renal function and massive proteinuria. Both patients failed to respond to immunosuppressive medications; however, rituximab, an anti-CD20 antibody, was effective in preserving renal function in one patient and eliminating the need for hemodialysis in the other. In one patient, histologic regression of abnormalities was documented over 3years post-treatment. Both patients have remained off other immunosuppressive medication for a prolonged period with stable renal function. These cases are, to our knowledge, the first reported successful treatment of C1q nephropathy with rituximab. Japanese Society of Nephrology, 2010 C1qN nationallicence Anti-CD20 nationallicence Sinha Aditi Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut Nast Cynthia Department of Pathology, UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA aut Hristea Ionut Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut Vo Ashley Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut Jordan Stanley Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut Clinical and Experimental Nephrology Springer Japan 15/1(2011-02-01), 164-170 1342-1751 15:1<164 2011 15 10157 https://doi.org/10.1007/s10157-010-0377-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-010-0377-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sinha Aditi Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Nast Cynthia Department of Pathology, UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA aut NATIONALLICENCE 700 1- Hristea Ionut Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Vo Ashley Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Jordan Stanley Transplant Immunotherapy Program, Division of Nephrology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 590 W, 90048, Los Angeles, CA, USA aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/1(2011-02-01), 164-170 1342-1751 15:1<164 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer